Alligator Bioscience: LOI Signals Potential Path Forward for Mitazalimab - Redeye

Alligator Bioscience has announced a letter-of-intent (LOI) with Unicancer regarding mitazalimab, outlining a potential path toward a Phase III program and signalling external interest in advancing the asset. We view the update as positive and consider the share price reaction of around 20% to be reasonable given the improved visibility on a potential way forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/1159386/alligator-bioscience-loi-signals-potential-path-forward-for-mitazalimab?utm_source=finwire&utm_medium=RSS